Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway
- 15 February 2009
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 182 (4), 2532-2541
- https://doi.org/10.4049/jimmunol.0802948
Abstract
TNF-α has both proinflammatory and immunoregulatory functions. Whereas a protective role for TNF administration in systemic lupus erythematosus (SLE)-prone (New Zealand Black × New Zealand White)F1 mice has been established, it remains uncertain whether this effect segregates at the individual TNFR. We generated SLE-prone New Zealand Mixed 2328 mice genetically deficient in TNFR1, in TNFR2, or in both receptors. Doubly-deficient mice developed accelerated pathological and clinical nephritis with elevated levels of circulating IgG anti-dsDNA autoantibodies and increased numbers of CD4+ T lymphocytes, especially activated memory (CD44highCD62Llow) CD4+ T cells. We show that these cells expressed a Th17 gene profile, were positive for IL-17 intracellular staining by FACS, and produced exogenous IL-17 in culture. In contrast, immunological, pathological, and clinical profiles of mice deficient in either TNFR alone did not differ from those in each other or from those in wild-type controls. Thus, total ablation of TNF-α-mediated signaling was highly deleterious to the host in the New Zealand Mixed 2328 SLE model. These observations may have profound ramifications for the use of TNF and TNFR antagonists in human SLE and related autoimmune disorders, as well as demonstrate, for the first time, the association of the Th17 pathway with an animal model of SLE.Keywords
This publication has 68 references indexed in Scilit:
- The role of tumor necrosis factor-alpha in systemic lupus erythematosusArthritis Research & Therapy, 2008
- Signal transduction pathways and transcriptional regulation in the control of Th17 differentiationSeminars in Immunology, 2007
- TNFα blockade in human diseases: An overview of efficacy and safetyClinical Immunology, 2007
- Th17: the third member of the effector T cell trilogyCurrent Opinion in Immunology, 2007
- Differential Functions of Tumor Necrosis Factor Receptor 1 and 2 Signaling in Ischemia-Mediated Arteriogenesis and AngiogenesisThe American Journal of Pathology, 2006
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- G1 arrest and high expression of cyclin kinase and apoptosis inhibitors in accumulated activated/memory phenotype CD4+ cells of older lupus miceEuropean Journal of Immunology, 1997
- Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retinaEuropean Journal of Immunology, 1996
- Modulation of the immunoglobulin dysregulation in GvH- and SLE-like diseases by the murine IL-4 receptor (IL-4-R)Inflammation Research, 1995
- Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 miceClinical Immunology and Immunopathology, 1989